TY  - JOUR
T1  - ANtiviral therapy and hepatitis b virus–related hepatocellular carcinoma recurrence—reply
AU  - Wu C, Hsu Y
Y1  - 2013/02/27
N1  - 10.1001/jama.2013.574
JO  - JAMA
SP  - 765
EP  - 767
VL  - 309
IS  - 8
N2  - 
In Reply: Dr Hsu and Ms Yeh and colleagues raise concerns about the designation of our study population, given that the Taiwan National Health Insurance Research Database lacked direct information for determining curativeness of resection, pathological details, and cancer stage. These limitations were addressed in our study by restricting enrollment to patients who received liver resection as the only treatment for HCC. Had the resection been incomplete, patients would most likely have had additional surgery or other treatment and been excluded.1

SN  - 0098-7484
M3  - doi: 10.1001/jama.2013.574
UR  - http://dx.doi.org/10.1001/jama.2013.574
ER  -